Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0043346 (
xeroderma pigmentosum
)
2,924
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
RASSF1A
may be the most frequently inactivated tumor suppressor identified in human cancer so far. It is a proapoptotic Ras effector and plays an important role in the apoptotic DNA damage response (DDR). We now show that in addition to DDR regulation,
RASSF1A
also plays a key role in the DNA repair process itself. We show that
RASSF1A
forms a DNA damage-regulated complex with the key DNA repair protein
xeroderma pigmentosum
A (XPA). XPA requires
RASSF1A
to exert full repair activity, and
RASSF1A
-deficient cells exhibit an impaired ability to repair DNA. Moreover, a cancer-associated
RASSF1A
single-nucleotide polymorphism (SNP) variant exhibits differential XPA binding and inhibits DNA repair. The interaction of XPA with other components of the repair complex, such as replication protein A (RPA), is controlled in part by a dynamic acetylation/deacetylation cycle. We found that
RASSF1A
and its SNP variant differentially regulate XPA protein acetylation, and the SNP variant hyperstabilizes the XPA-RPA70 complex. Thus, we identify two novel functions for
RASSF1A
in the control of DNA repair and protein acetylation. As
RASSF1A
modulates both apoptotic DDR and DNA repair, it may play an important and unanticipated role in coordinating the balance between repair and death after DNA damage.
...
PMID:The RASSF1A tumor suppressor regulates XPA-mediated DNA repair. 2536 79